All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT. We asked about highlights for polycythemia vera (PV) from the 62nd ASH Annual Meeting and Exposition.
ASH 2020: Highlights for polycythemia vera
Barbui outlines three studies on PV therapies. This includes an update for a 5-year study evaluating ropeginterferon alfa-2b, a phase II trial evaluating the novel hepcidin-mimetic PTG-300, and a study observing discontinuation of interferon treatment in patients with PV.
FDA accepts Biologics License Application of ropeginterferon alfa-2b for polycythemia vera
On June 4, 2020, the U.S. Food and Drug Administration (FDA) accepted a Biologics License Application (BLA) for ropeginterferon alfa-2b (P1101) for the...
Is the hepcidin-mimetic PTG‑300 a promising treatment for therapeutic phlebotomy-dependent PV?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Marina Kremyanskaya, Icahn School of Medicine at...
Subscribe to get the best content related to MPN delivered to your inbox